Edition:
India

Corbus Pharmaceuticals Holdings Q4 Loss Per Share $0.30


Tuesday, 12 Mar 2019 

Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES.Q4 LOSS PER SHARE $0.30.Q4 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.CONTINUED PROGRESS IN FOUR ONGOING CLINICAL STUDIES AS LENABASUM MOVES TOWARDS EXPECTED 2020 TOPLINE DATA READOUTS IN SYSTEMIC SCLEROSIS AND CYSTIC FIBROSIS STUDIES.SECOND CLINICAL CANDIDATE CRB-4001 EXPECTED TO COMMENCE CLINICAL STUDIES IN 2019.CORBUS PHARMACEUTICALS HOLDINGS - EXPECTS CURRENT CASH & CASH EQUIVALENTS TO FUND OPERATIONS INTO Q4 OF 2020, BASED ON CURRENT PLANNED EXPENDITURES.CORBUS PHARMACEUTICALS HOLDINGS - CO'S CASH AND CASH EQUIVALENTS BALANCE AT DECEMBER 31, 2018 WAS ABOUT $41.7 MILLION. 

Company Quote